NumFin

ARCA biopharma, Inc.

Sümbol: ABIO

NASDAQ

3.26

USD

Turuhind täna

  • -8.6266

    P/E suhe

  • -0.1918

    PEG suhe

  • 47.29M

    MRK Cap

  • 0.00%

    DIV tootlus

ARCA biopharma, Inc. (ABIO) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete ARCA biopharma, Inc. (ABIO) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 5.652 M, mis on 1.153 % gowth. Kogu perioodi keskmine brutokasum on 5.979 M, mis on 0.795 %. Keskmine brutokasumi suhtarv on 0.538 %. Ettevõtte eelmise aasta tulemuse puhaskasv on -0.423 %, mis on võrdne -0.189 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes ARCA biopharma, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.121. Käibevara valdkonnas on ABIO aruandlusvaluutas 37.592. Märkimisväärne osa neist varadest, täpsemalt 37.431, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.118%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 0, kui neid on, aruandlusvaluutas. See näitab erinevust 0.000% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 0.204 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 0.000%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 37.02 aruandlusvaluutas. Selle aspekti aastane muutus on -0.112%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 0, varude hind on 0 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 0.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

balance-sheet.row.cash-and-short-term-investments

151.9837.442.453.4
49.1
8.4
6.6
11.8
21.2
38.8
15.4
16.8
2.9
5.9
7
7.8
51
97.6
153.1
70.3
50.6
34.2
2.2
12.3
2.7
30.7
21.6
23.2
6.7

balance-sheet.row.short-term-investments

0000
0
0
0
3
13.8
0
0
0
0
0
0
0
15.1
65.5
92.8
32.6
33.8
21
0
0
0
17
0
0
0

balance-sheet.row.net-receivables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0.4
0.6
8.6
0.1
0.3
0.3
0.6
1.1
0
1.3
0.7
2.2
0.1

balance-sheet.row.inventory

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12.3
12.6
0
0
1.9
0
0
0
0
0

balance-sheet.row.other-current-assets

1.930.20.31.1
0.9
0.1
0.2
0.5
0.3
0.1
0.1
0.2
0.1
0.3
0.1
0.5
0.7
1.8
4.7
3.1
2.5
5.3
3
1
2.9
1
25.9
34.8
0.4

balance-sheet.row.total-current-assets

153.9137.642.754.4
50
8.5
6.8
12.3
21.4
38.9
15.5
16.9
3
6.2
7.2
8.3
52.1
100
166.3
85.8
66
39.9
5.9
16.3
5.6
33
48.2
60.2
7.2

balance-sheet.row.property-plant-equipment-net

0.870.30.40.5
0.4
0
0
0
0.1
0
0
0
0
0.1
0.7
1
6.8
8.9
12
15.2
6
10
15.1
19
12.5
8.4
6.9
3.9
1.6

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
4.7
4.7
4.7
4.7
4.7
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7.1
7
7.5
2.1
3
1.1
1.8
0.7
0.7
0.6

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
4.7
4.7
7.1
7
7.5
2.1
3
1.1
1.8
0.7
0.7
0.6

balance-sheet.row.long-term-investments

0000
0
0
0
0
2.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0.05000
0
0
0
0
0.8
0.6
0.6
0.1
0.1
0.2
0.3
0.1
7.1
7.1
1.4
0
0.2
0.5
3.9
1.6
2.1
2.2
2.1
2.2
0

balance-sheet.row.total-non-current-assets

0.930.30.40.5
0.5
0.1
0
0.1
3.2
0.7
0.6
0.2
0.2
0.3
1
1.1
13.9
20.7
18.1
22.3
13.3
18
21.2
23.6
15.7
12.4
9.7
6.8
2.2

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

154.8337.943.154.9
50.4
8.5
6.8
12.4
24.6
39.6
16.1
17.1
3.2
6.5
8.2
9.4
66
120.7
184.4
108
79.3
57.8
27.1
39.9
21.3
45.4
57.9
67
9.4

balance-sheet.row.account-payables

1.450.40.31.1
1.8
0.4
0.2
0.6
1.2
0.4
0.8
0.6
0.1
0.3
0.4
0.5
1.3
2.8
7
4.9
3.1
1.7
2.2
3.2
2
1.5
1.9
1.6
0.6

balance-sheet.row.short-term-debt

0.290.10.10.1
0
0
0
0
0
0
0
0
0
0
0
0
8
13
3.7
8.3
4.4
4.7
1.2
2.5
2.4
2.1
1.4
0.3
0.3

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

0.670.20.30.4
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
3.8
11.1
15.5
5
6.2
4.7
5.2
4.5
0.6
0.8

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0
0
0
0.2
0.3
5
16.1
44.5
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

3.840.60.82.4
1.7
0.5
0.6
1.4
1.2
1.1
0.6
0.9
0.2
0.5
0.7
1
0.4
2.2
29.5
29.9
10.5
5.6
22.6
8.6
3.8
7.3
2.6
1.5
0.3

balance-sheet.row.total-non-current-liabilities

0.670.20.30.4
0.4
0
0
0
0
0
0
0
0
0
0.2
0.3
12.2
34.8
70.7
6.4
11.1
21
5
6.4
4.7
5.3
4.4
0.7
0.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0.670.20.30.4
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
1.1
1
2.2
0
0
0
0
0

balance-sheet.row.total-liab

5.480.81.43.9
3.9
0.9
0.8
2.1
2.4
1.5
1.4
1.5
0.3
0.8
1.4
2
23.5
53
114.6
51.3
33.7
35.1
31.6
24.4
12.9
16.2
10.3
4.1
2

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14.8

balance-sheet.row.common-stock

0.06000
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0.1
0
0
0
0
0
0
82.5
0
0
0

balance-sheet.row.retained-earnings

-753.37-188.7-183.4-173.5
-154.2
-144.4
-138.9
-131
-112.5
-96.1
-84.6
-74.9
-68
-63.7
-58.3
-49.9
-500.4
-470.5
-458.2
-327.7
-256
-203.6
-153.4
-108.4
-71.9
-49.7
-31.1
-14.8
-8.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

0000
0
0
0
0
0
-0.4
-0.4
-0.5
-0.5
-0.5
-1
-0.6
0
0
0
-0.3
-0.2
0
0
-0.1
0
-3.6
-3
-1.3
-0.5

balance-sheet.row.other-total-stockholders-equity

902.67225.7225.1224.5
200.7
152
145
141.3
134.7
134.5
99.7
91
71.4
69.9
66
57.9
542.9
538.1
528
384.6
301.8
226.3
148.8
123.8
80.3
0
81.7
79
16.1

balance-sheet.row.total-stockholders-equity

149.353741.751
46.5
7.6
6
10.3
22.2
38.1
14.7
15.6
2.9
5.7
6.8
7.4
42.5
67.7
69.8
56.8
45.6
22.7
-4.6
15.4
8.4
29.2
47.6
62.9
7.4

balance-sheet.row.total-liabilities-and-stockholders-equity

154.8337.943.154.9
50.4
8.5
6.8
12.4
24.6
39.6
16.1
17.1
3.2
6.5
8.2
9.4
66
120.7
184.4
108
79.3
57.8
27.1
39.9
21.3
45.4
57.9
67
9.4

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0
0
0
0
0

balance-sheet.row.total-equity

149.353741.751
46.5
7.6
6
10.3
22.2
38.1
14.7
15.6
2.9
5.7
6.8
7.4
42.5
67.7
69.8
56.8
45.6
22.7
-4.6
15.5
8.4
29.2
47.6
62.9
7.4

balance-sheet.row.total-liabilities-and-total-equity

154.83---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0000
0
0
0
3
16.1
0
0
0
0
0
0
0
15.1
65.5
92.8
32.6
33.8
21
0
0
0
17
0
0
0

balance-sheet.row.total-debt

0.720.30.30.4
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
3.8
12.1
15.5
20.2
6.2
8.7
7.1
7.3
5.9
0.9
1.1

balance-sheet.row.net-debt

-151.26-37.2-42.2-53
-48.7
-8.3
-6.6
-8.7
-7.4
-38.8
-15.4
-16.8
-2.9
-5.9
-7
-7.8
-35.9
-32.1
-56.6
-25.7
-1.3
7.1
4
-3.6
4.4
-6.4
-15.7
-22.3
-5.6

Rahavoogude aruanne

ARCA biopharma, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 0.541 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0, mis tähistab 0.000 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 0.03 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli 0.000. See on 0.000 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 0.11, 0, 0, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 0, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

cash-flows.row.net-income

-6-5.3-9.9-19.3
-9.7
-5.5
-7.9
-18.5
-16.4
-11.4
-9.7
-6.9
-4.3
-5.4
-8.4
-9.1
-29.9
-12.3
-130.6
-71.6
-52.5
-50.2
-45
-36.5
-22.3
-18.5
-16.4
-6.5
-4.8

cash-flows.row.depreciation-and-amortization

0.10.10.10.1
0.1
0.1
0
0.4
0.3
0
0
0
0
0.6
0.3
0.5
2.3
2.3
3.2
2.7
4.1
5.5
6.3
5.1
3.1
3
2
1.2
0.4

cash-flows.row.deferred-income-tax

-0.77-0.90-1.1
0.9
-0.1
0
0
0
0
0
0
0
3.4
0
-2.3
4.7
0
13.6
1.2
1.5
0.7
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0.60.70.60.5
0
0.2
0.3
0.5
0.6
0.6
0.6
0.3
0.3
0.3
0.5
0.8
4.6
0
11.3
0.6
0.3
0.5
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0.36-0.5-1.70
1.9
0.4
-0.6
0.1
0.4
0.1
-0.4
1.3
-0.1
-0.5
-0.4
-13.1
-28.3
-48.6
53.8
8.1
-1.2
-3.8
22.5
33
9.4
2.6
2.6
-2.8
0.1

cash-flows.row.account-receivables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38.4
0.2
0.1
0.5
-0.6
0
0
0
0
0
0

cash-flows.row.inventory

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12.4
-1.6
-8.6
-28.9
44.8
0
0
0
0
0
0

cash-flows.row.account-payables

0.160-0.8-0.4
1.1
0.2
-0.4
-0.6
0.8
-0.4
0.2
0.5
-0.2
-0.1
-0.1
-2.5
-1
0
2.1
1.8
1
-1.1
-1
0
0
0
0
0
0

cash-flows.row.other-working-capital

0.36-0.5-0.90.4
0.8
0.3
-0.2
0.7
-0.4
0.5
-0.6
0.8
0.1
-0.4
-0.3
-10.7
-27.2
-48.6
0.8
7.8
6.3
25.8
-20.7
33
9.4
2.6
2.6
-2.8
0.1

cash-flows.row.other-non-cash-items

0.920.901.1
-0.9
0.1
0
0.1
0.2
0.2
0.1
0
0
-5.4
-0.3
-18.5
0.1
12.6
11.7
0
-2.3
2.2
-15.1
-23.1
-11.2
-0.1
0.1
0
0

cash-flows.row.net-cash-provided-by-operating-activities

-4.95000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0000
0
0
0
0
0
0
0
0
0
0
0
-0.2
-0.2
-0.4
-2.4
-2.6
-0.7
-0.3
-2.1
-12.6
-8.3
-4.4
-4.6
-3.1
-0.9

cash-flows.row.acquisitions-net

0000
0
0
0
0
0
0
0
0
0
0
0
30.4
0
0.1
0
0
0
0.7
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0000
0
0
0
-5.5
-20.5
0
0
0
0
0
0
0
-44.6
-116.6
-114.6
-62.8
-63.8
-20.2
0
0
-57.1
-16.4
-44.5
-38.9
0

cash-flows.row.sales-maturities-of-investments

0000
0
0
3
18.4
4.1
0
0
0
0
0
0.3
15.1
95
143.9
54.4
64.2
50.9
22.5
0
0
74.1
24.3
53.6
5
0

cash-flows.row.other-investing-activites

0000
0
0
0
0
0
0
0
0
0
2
0
0.3
0
-6
0.5
0
0
25.7
0.5
-0.5
0
0
0
-0.1
0

cash-flows.row.net-cash-used-for-investing-activites

0000
0
0
3
12.9
-16.4
0
0
0
0
2
0.3
45.6
50.2
21.1
-62.1
-1.2
-13.6
28.4
-1.6
-13.1
8.7
3.5
4.5
-37.1
-0.9

cash-flows.row.debt-repayment

0000
-0.4
-0.3
0
0
0
0
0
0
0
0
0
-4
0
0
0
0
0
-2.3
-2.5
0
0
0
0
0
0

cash-flows.row.common-stock-issued

00024.1
50.9
7.3
3.5
6.6
0
37
9
1.7
1.5
4.7
7.7
0.1
0.2
0.4
130
84.3
71.8
28
14.8
22.2
1.5
0.2
0.5
61.5
10.2

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

000-1
-2
-0.4
-0.4
-0.7
0
-3
-1
17.4
-0.5
-0.9
-0.3
0
0
-3.8
-8.3
-3.2
-4.4
1.9
10.5
22.1
-0.2
1.5
5.1
0.1
1

cash-flows.row.net-cash-used-provided-by-financing-activities

00023.1
48.5
6.6
3.1
5.8
0
34
8
19.2
1.1
3.9
7.3
-3.9
0.2
-3.4
121.7
81.2
67.4
27.6
22.8
44.3
1.3
1.6
5.6
61.6
11.2

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-4.95-5-10.94.3
40.7
1.8
-2.1
1.3
-31.4
23.4
-1.4
13.8
-3
-1.1
-0.7
0
3.8
-28.3
22.6
21
3.7
10.9
-10.1
9.6
-11
-7.9
-1.6
16.4
6

cash-flows.row.cash-at-end-of-period

151.9837.442.453.4
49.1
8.4
6.6
8.7
7.4
38.8
15.4
16.8
2.9
5.9
7
7.8
35.9
32.1
60.3
37.8
16.8
13.1
2.2
12.3
2.7
13.7
21.6
23.1
6.8

cash-flows.row.cash-at-beginning-of-period

156.9242.453.449.1
8.4
6.6
8.7
7.4
38.8
15.4
16.8
2.9
5.9
7
7.8
7.7
32.1
60.3
37.8
16.8
13.1
2.2
12.3
2.7
13.7
21.6
23.2
6.7
0.8

cash-flows.row.operating-cash-flow

-4.95-5-10.9-18.8
-7.7
-4.8
-8.2
-17.5
-15
-10.5
-9.4
-5.3
-4.1
-7
-8.3
-41.7
-46.5
-46
-37.1
-59
-50.1
-45.1
-31.3
-21.5
-21
-13
-11.7
-8.1
-4.3

cash-flows.row.capital-expenditure

0000
0
0
0
0
0
0
0
0
0
0
0
-0.2
-0.2
-0.4
-2.4
-2.6
-0.7
-0.3
-2.1
-12.6
-8.3
-4.4
-4.6
-3.1
-0.9

cash-flows.row.free-cash-flow

-4.95-5-10.9-18.8
-7.7
-4.8
-8.2
-17.5
-15
-10.5
-9.4
-5.3
-4.1
-7
-8.3
-41.9
-46.7
-46.3
-39.5
-61.6
-50.8
-45.4
-33.4
-34.1
-29.3
-17.4
-16.3
-11.2
-5.2

Kasumiaruande rida

ARCA biopharma, Inc. tulud muutusid võrreldes eelmise perioodiga 0.000%. ABIO brutokasum on teatatud -0.11. Ettevõtte tegevuskulud on 7.3, mille muutus võrreldes eelmise aastaga on -31.144%. Kulud amortisatsioonikulud on 0.11, mis on -0.026% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 7.3, mis näitab -31.144% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab 0.311% kasvu võrreldes eelmise aastaga. Tegevustulu on -7.3, mis näitab -0.311% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on -0.423%. Eelmise aasta puhaskasum oli -5.34.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

income-statement-row.row.total-revenue

0.18000
0
0
0
0
0
0
0
0
0
0
0
0
15.3
46.9
3.9
0.5
0.2
2.3
26.4
24.6
15.6
6.4
9.6
6.2
0.4

income-statement-row.row.cost-of-revenue

0.10.10.10.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-3.1
-3
-2
-1.2
-0.4

income-statement-row.row.gross-profit

0.07-0.1-0.1-0.1
-0.1
-0.1
0
0
0
0
0
0
0
0
0
0
15.3
46.9
3.9
0.5
0.2
2.3
26.4
24.6
18.7
9.4
11.6
7.4
0.8

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0.79---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

7.19---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

2.3---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0000
0
0
0
0
0
0
0
0
0
0
0
0
-1.3
2.3
24.5
0
0.2
1.2
0
0
3.1
3
2
1.2
0.4

income-statement-row.row.operating-expenses

7.967.310.619.3
9.8
5.8
8.1
18.7
16.6
11.5
9.7
6.9
4.3
7.4
9.2
22.9
41.4
63.4
144.5
73.6
48.8
51.5
68.3
60
41.5
29.3
30.7
15.5
5.8

income-statement-row.row.cost-and-expenses

7.987.310.619.3
9.8
5.8
8.1
18.7
16.6
11.5
9.7
6.9
4.3
7.4
9.2
22.9
41.4
63.4
144.5
73.6
48.8
51.5
68.3
60
38.3
26.3
28.7
14.3
5.4

income-statement-row.row.interest-income

1.9820.70
0
0.2
0.2
0.2
0.2
0
0
0
0
0
0.8
0.2
0
6.7
8.4
2.2
2.9
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

0.4500.70
0
0
0
0
0
0
0
0
0
0
0
0.2
0
-0.1
-0.3
-0.5
-0.5
-1.7
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

2.3---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

1.9820.70
0
0.2
0.2
0.2
0.2
0
0
0
0
2
0.8
11.4
-6.2
-2.3
-24.5
0.3
-0.2
-1.2
-2.1
-0.8
0
0
2.7
1.7
0.3

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0000
0
0
0
0
0
0
0
0
0
0
0
0
-1.3
2.3
24.5
0
0.2
1.2
0
0
3.1
3
2
1.2
0.4

income-statement-row.row.total-operating-expenses

1.9820.70
0
0.2
0.2
0.2
0.2
0
0
0
0
2
0.8
11.4
-6.2
-2.3
-24.5
0.3
-0.2
-1.2
-2.1
-0.8
0
0
2.7
1.7
0.3

income-statement-row.row.interest-expense

0.4500.70
0
0
0
0
0
0
0
0
0
0
0
0.2
0
-0.1
-0.3
-0.5
-0.5
-1.7
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

0.10.10.10
0
0.3
0
0.4
0.3
0
0
0
0
0.6
0.3
0.5
2.3
2.3
3.2
2.7
4.1
5.5
6.3
5.1
3.1
3
2
1.2
0.4

income-statement-row.row.ebitda-caps

-7.94---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-7.98-7.3-10.6-19.3
-9.8
-5.8
-8.1
-18.7
-16.6
-11.5
-9.7
-6.9
-4.3
-7.4
-9.2
-36.7
-33.3
-18.9
-140.6
-73
-48.6
-49.2
-43.9
-36.2
-22.7
-19.9
-19.1
-8.1
-5

income-statement-row.row.income-before-tax

-6-5.3-9.9-19.3
-9.7
-5.6
-8
-18.6
-16.4
-11.4
-9.7
-6.9
-4.3
-5.4
-8.4
-11.4
-29.9
-12.3
-130.6
-71.6
-52.5
-50.2
-76.8
-36.8
0
0
-16.4
-6.4
-4.7

income-statement-row.row.income-tax-expense

0.45-0.1-0.7-0.1
0
-0.2
0
-0.1
0.2
0
0
0
0
0
0.8
-2.3
3.8
-4.3
-10
-1.4
3.8
0.9
3.1
-0.3
-0.5
-1.4
-2.7
-1.6
-0.2

income-statement-row.row.net-income

-5.48-5.3-9.3-19.2
-9.7
-5.5
-7.9
-18.5
-16.5
-11.4
-9.7
-6.9
-4.3
-5.4
-8.4
-9.1
-29.9
-12.3
-130.6
-71.6
-52.5
-50.2
-45
-36.5
-22.3
-18.5
-16.4
-6.5
-4.8
Sarnased aktsiad
Sind võib huvitada ka:
SRNE
Sorrento Therapeutics, Inc..
0.015 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.97 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
300 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.1 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.35 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Korduma kippuv küsimus

Mis on ARCA biopharma, Inc. (ABIO) koguvara?

ARCA biopharma, Inc. (ABIO) koguvara on 37861000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 176000.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.426.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -0.341.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on -31.136.

Mis on ettevõtte kogutulu?

Kogutulu on -45.352.

Mis on ARCA biopharma, Inc. (ABIO) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -5339000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 280000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 7296000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 35903000.000.